内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-19 · 构建时间： 2026-10-19 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Lyell Immunopharma, Inc.

LYEL · Nasdaq · CIK 0001806952 · Healthcare · Biotechnology

内部人信号

当前没有活跃买入信号

0 qualifying P purchase groups
当前 180 天评分窗口

20 同一窗口内观察到的 Form 4 交易行
16 sales · 4 期权、代扣税、授予、赠与或其他交易行

最近一次合资格买入2026-03-06 · ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · $12.5M

为什么没有活跃信号？

买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成

活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。

Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算

为什么没有分数？

  • 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
  • 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。

卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。

买方广度、集中度与聚集买入

合资格买入进入 180 天研究窗口后，这些模块才会启用。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
Innovative Cellular Therapeutics Holdings LtdTenPercentOwner
○○▼▼○○
Seely LynnPresident and CEO
▼▼▼
Lee Gary K.Chief Scientific Officer
▼▼▼
Hill Stephen J.Chief Operating Officer
▼▼▼
Shook DavidChief Medical Officer
▼▼
Bulis Veronica SanchezVP, Corporate Controller
▼▼
● 买入▼ 卖出○ 其他

Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.

信号历史

暂无已记录的活跃信号快照

Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-06 · ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC.

近期 Form 4 活动

2买入
29卖出
8其他 Form 4 交易行
34SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出16 sale line(s) · 仅供背景
其他4 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

该股票尚未获取市场背景。每日任务会轮转处理美国股票池。

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
1,263,394
上期报告
1,187,902
日均成交量
170,775
回补天数
7.4

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-03-06ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT买入 (P)Common Stock488,090USD 25.61USD 12,499,985SEC 申报 ↗
2026-03-06ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC买入 (P)Common Stock488,090USD 25.61USD 12,499,985SEC 申报 ↗
2025-03-31BRAWLEY OTIS W买入 (P)Common Stock35,640USD 0.56USD 19,958SEC 申报 ↗
2025-03-21Ramachandra Sumant买入 (P)Common Stock200,000USD 0.58USD 116,000SEC 申报 ↗
2025-03-17Newton Charles W.买入 (P)Common Stock200,000USD 0.56USD 112,000SEC 申报 ↗
2025-03-14Seely Lynn买入 (P)Common Stock175,000USD 0.61USD 106,750SEC 申报 ↗
2025-03-14Klausner Richard买入 (P)Common Stock158,000USD 0.60USD 94,800SEC 申报 ↗
2021-06-21FRIEDMAN CATHY买入 (P)Common Stock17,648USD 17.00USD 300,016SEC 申报 ↗

Form 4 申报证据

39 transaction lines in the latest 365-day window; 84 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-10-12Aguirre Jarrad Mattieu卖出 (S)Common Stock422USD 8.63USD 3,642SEC 申报 ↗
2026-09-10Shook David卖出 (S)Common Stock500USD 12.70USD 6,350SEC 申报 ↗
2026-08-21Seely Lynn卖出 (S)Common Stock9,589USD 15.54USD 149,013SEC 申报 ↗
展开近期 Form 4 证据 (30 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-10-12Aguirre Jarrad Mattieu卖出 (S)Common Stock422USD 8.63USD 3,642SEC 申报 ↗
2026-09-10Shook David卖出 (S)Common Stock500USD 12.70USD 6,350SEC 申报 ↗
2026-08-21Seely Lynn卖出 (S)Common Stock9,589USD 15.54USD 149,013SEC 申报 ↗
2026-08-21Lee Gary K.卖出 (S)Common Stock1,457USD 15.54USD 22,642SEC 申报 ↗
2026-08-21Hill Stephen J.卖出 (S)Common Stock989USD 15.54USD 15,369SEC 申报 ↗
2026-08-10Seely Lynn卖出 (S)Common Stock390USD 14.34USD 5,593SEC 申报 ↗
2026-08-10Lee Gary K.卖出 (S)Common Stock131USD 14.34USD 1,879SEC 申报 ↗
2026-08-10Hill Stephen J.卖出 (S)Common Stock89USD 14.34USD 1,276SEC 申报 ↗
2026-08-10Bulis Veronica Sanchez卖出 (S)Common Stock621USD 14.34USD 8,905SEC 申报 ↗
2026-07-27Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock44,000USD 0.00USD 0SEC 申报 ↗
2026-07-27Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock38,500USD 0.00USD 0SEC 申报 ↗
2026-07-17Innovative Cellular Therapeutics Holdings Ltd卖出 (S)Common Stock10USD 13.70USD 137SEC 申报 ↗
2026-07-16Innovative Cellular Therapeutics Holdings Ltd卖出 (S)Common Stock10USD 13.73USD 137SEC 申报 ↗
2026-06-29Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock76,000USD 0.00USD 0SEC 申报 ↗
2026-06-15Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock66,500USD 0.00USD 0SEC 申报 ↗
2026-06-10Shook David卖出 (S)Common Stock1,977USD 12.64USD 24,989SEC 申报 ↗
2026-05-11Seely Lynn卖出 (S)Common Stock388USD 18.91USD 7,337SEC 申报 ↗
2026-05-11Lee Gary K.卖出 (S)Common Stock130USD 18.92USD 2,460SEC 申报 ↗
2026-05-11Hill Stephen J.卖出 (S)Common Stock89USD 18.92USD 1,684SEC 申报 ↗
2026-05-11Bulis Veronica Sanchez卖出 (S)Common Stock217USD 18.91USD 4,103SEC 申报 ↗
2026-03-06ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT买入 (P)Common Stock488,090USD 25.61USD 12,499,985SEC 申报 ↗
2026-03-06ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC买入 (P)Common Stock488,090USD 25.61USD 12,499,985SEC 申报 ↗
2026-02-11Seely Lynn卖出 (S)Common Stock7,455USD 23.39USD 174,372SEC 申报 ↗
2026-02-11Lee Gary K.卖出 (S)Common Stock1,671USD 23.39USD 39,085SEC 申报 ↗
2026-02-11Hill Stephen J.卖出 (S)Common Stock1,236USD 23.39USD 28,910SEC 申报 ↗
2026-02-10Seely Lynn卖出 (S)Common Stock438USD 23.12USD 10,127SEC 申报 ↗
2026-02-10Lee Gary K.卖出 (S)Common Stock147USD 23.12USD 3,399SEC 申报 ↗
2026-02-10Hill Stephen J.卖出 (S)Common Stock109USD 23.12USD 2,520SEC 申报 ↗
2026-02-10Bulis Veronica Sanchez卖出 (S)Common Stock254USD 23.12USD 5,872SEC 申报 ↗
2026-02-10Bulis Veronica Sanchez奖励／授予 (A)Common Stock8,750USD 0.00USD 0SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-19
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码LYEL
CIK0001806952
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史84 transaction lines from 2021-06-21 to 2026-10-12
8 P purchase lines · 43 S sale lines · 33 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.